201
TITLE: Third-line salvage chemotherapy for recurrent cervical cancer.
AUTHORS: Manders, DB; Purinton, SC; Lea, J; David Scott Miller ; Kehoe, SM; Richardson, DL;
PUBLISHED: 2011, SOURCE: Journal of Clinical Oncology, VOLUME: 29, ISSUE: 15_suppl
INDEXED IN: CrossRef
202
TITLE: A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: A gynecologic oncology group trial. A Gynecologic Oncology Group Trial
AUTHORS: Russell J Schilder; John A Blessing; Mark S Shahin; David Scott Miller ; Krishnansu Sujata Tewari; Carolyn Y Muller; David P Warshal; Scott McMeekin; Jacob Rotmensch;
PUBLISHED: 2010, SOURCE: International Journal of Gynecological Cancer, VOLUME: 20, ISSUE: 7
INDEXED IN: Scopus CrossRef: 13
203
TITLE: An update on endometrial cancer
AUTHORS: Todd Boren; David Scott Miller ;
PUBLISHED: 2010, SOURCE: Texas medicine, VOLUME: 106, ISSUE: 9
INDEXED IN: Scopus
204
TITLE: PRO: All patients with serous and clear cell carcinomas of the endometrium should receive chemotherapy as part of their treatment  Full Text
AUTHORS: Todd P Boren; David Scott Miller ;
PUBLISHED: 2010, SOURCE: Clinical Ovarian Cancer, VOLUME: 3, ISSUE: 2
INDEXED IN: Scopus CrossRef
205
TITLE: Promoter hypermethylation of CIDEA, HAAO and RXFP3 associated with microsatellite instability in endometrial carcinomas  Full Text
AUTHORS: Yi Wen Huang; Jingqin Luo; Yu I Weng; David G Mutch; Paul J Goodfellow; David Scott Miller ; Tim H M Huang;
PUBLISHED: 2010, SOURCE: Gynecologic Oncology, VOLUME: 117, ISSUE: 2
INDEXED IN: Scopus CrossRef: 38
206
TITLE: Should all patients with serous and clear cell endometrial carcinoma receive adjuvant chemotherapy?
AUTHORS: Todd P Boren; David Scott Miller ;
PUBLISHED: 2010, SOURCE: Women's Health, VOLUME: 6, ISSUE: 6
INDEXED IN: Scopus CrossRef: 2
207
TITLE: The correlation of cone biopsy with findings at radical hysterectomy and the need for adjuvant radiation therapy.
AUTHORS: Boren, TP; Richardson, DL; Kehoe, SM; David Scott Miller ;
PUBLISHED: 2010, SOURCE: Journal of Clinical Oncology, VOLUME: 28, ISSUE: 15_suppl
INDEXED IN: CrossRef
208
TITLE: A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology  Full Text
AUTHORS: David Scott Miller ; John A Blessing; Richard D Drake; Robert Higgins; Scott S McMeekin; Louis V Puneky; Carolyn N Krasner;
PUBLISHED: 2009, SOURCE: Gynecologic Oncology, VOLUME: 115, ISSUE: 3
INDEXED IN: Scopus CrossRef: 31
209
TITLE: Chemo- and radiotherapy in adjuvant management of optimally debulked endometrial cancer
AUTHORS: David Scott Miller ; Gini Fleming; Marcus E Randall;
PUBLISHED: 2009, SOURCE: JNCCN Journal of the National Comprehensive Cancer Network, VOLUME: 7, ISSUE: 5
INDEXED IN: Scopus CrossRef: 4
210
TITLE: Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer
AUTHORS: Yi Wen Huang; Joseph C Liu; Daniel E Deatherage; Jingqin Luo; David G Mutch; Paul J Goodfellow; David Scott Miller ; Tim H M Huang;
PUBLISHED: 2009, SOURCE: Cancer Research, VOLUME: 69, ISSUE: 23
INDEXED IN: Scopus CrossRef: 221
Page 21 of 32. Total results: 319.